Patients with increased body mass index were more likely to be treated with a SGLT2 inhibitor, probably because its pharmacological effect, i.e., urinary glucose excretion, accompanied not only by reduced blood glucose levels but also by reduced body weight [40], would be assumed by physicians to be suitable for patients with obesity. This evidence concerns the gene SLC5A2 and obesity disorder.